Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parabon NanoLabs has won a National Science Foundation (NSF) joint grant for the development of prostate cancer therapeutic, PJ-01, together with Janssen Research & Development, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Subscribe to our email newsletter
The PJ-01 development project will leverage Parabon’s Essemblix drug development platform to design macromolecules and nanoscale fabrication technology used in the production.
The NSF grant program funds technology enhancement for commercial partnerships (TECP) to promote joint development associations between the companies previously awarded small business innovation research grants and their partners.
Parabon NanoLabs president and CEO Dr. Steven Armentrout said the NSF TECP program besides funding the research allows small business innovators to establish important industry relationships.
"With intellectual partnership from Janssen’s creative scientists, we are confident this project will further validate our Essemblix platform," Dr. Armentrout added.
Parabon, in co-operation with Jansen, has designed PJ-01 to deliver an FDA approved drug formulation, docetaxel, targeting prostate tumor cells with reduced side effects and improved efficacy.
As part of the project, Janssen will test the compounds resulting from Essemblix in a cost controlled manner.
The project lead advisor and Janssen principal scientist Dr. Edward Lawson said, "We are excited about our collaboration with Parabon and the potential of this new technology to enable us to bring innovative treatments to patients faster."